Spitalul Clinic Judetean De Urgenta Sfantul Apostol Andrei Constanta
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Spitalul Clinic Judetean De Urgenta Sfantul Apostol Andrei Constanta, clinical research in cardiovascular diseases focuses on major conditions such as acute coronary syndrome, heart failure, and stroke-related risk. These studies are designed to test whether new treatments can better prevent serious events and improve outcomes alongside standard care.
- Reducing the risk of major cardiovascular events after a heart attack
- Evaluating protection against recurrent ischemic stroke
- Improving care for heart failure with systemic inflammation
This work reflects a strong interest in both prevention and treatment effectiveness, with a focus on lowering the chances of cardiovascular death, myocardial infarction, and related complications.
Nervous System Diseases
The site is also involved in nervous system diseases research, especially studies related to acute ischemic stroke, high-risk transient ischemic attack, and migraine. These trials aim to improve how acute neurological conditions are managed and to assess whether new therapies can offer safer, more effective symptom relief.
- Preventing further stroke events after acute neurological episodes
- Testing treatment options for migraine in children and adolescents
The pediatric department’s involvement highlights a broad interest in both urgent neurological care and longer-term support for younger patients.
Immune System Processes
Research in immune system processes at this hospital includes studies of respiratory syncytial virus prevention in infants and inflammation-linked heart disease. These trials are intended to explore whether targeted therapies can reduce infection-related illness and help control harmful inflammatory responses.
- Preventing RSV-associated lower respiratory infections in infants
- Studying inflammation as a contributor to heart failure outcomes
Overall, the research combines infection prevention with inflammation-focused care, showing interest in both pediatric protection and broader disease control.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Eli Lilly & Co.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S7trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Clinic Judetean De Urgenta Sfantul Apostol Andrei Constanta
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | Merck Sharp & Dohme LLC | Phase IV | Not Recruiting | Nov 2022 | Feb 2024 |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 4 | Unknown | 2020-10-30 | 2022-08-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.